Exelixis, Inc. (NASDAQ:EXEL) Director Sells $324,683.15 in Stock

Exelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Jack L. Wyszomierski sold 7,535 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total value of $324,683.15. Following the completion of the transaction, the director now directly owns 358,882 shares of the company's stock, valued at approximately $15,464,225.38. This trade represents a 2.06% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Exelixis Price Performance

Shares of Exelixis stock traded up $0.66 during trading on Friday, reaching $43.03. 2,335,750 shares of the stock traded hands, compared to its average volume of 2,331,064. The company has a market capitalization of $11.73 billion, a price-to-earnings ratio of 24.31, a P/E/G ratio of 1.13 and a beta of 0.28. Exelixis, Inc. has a 52-week low of $21.36 and a 52-week high of $48.85. The business has a fifty day simple moving average of $38.90 and a two-hundred day simple moving average of $36.58.

Hedge Funds Weigh In On Exelixis

Institutional investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in shares of Exelixis during the 4th quarter valued at approximately $17,046,000. Allspring Global Investments Holdings LLC raised its stake in Exelixis by 82.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock valued at $52,884,000 after purchasing an additional 704,786 shares in the last quarter. Proficio Capital Partners LLC bought a new position in Exelixis during the fourth quarter valued at $706,000. Wells Fargo & Company MN grew its stake in shares of Exelixis by 1,637.9% in the 4th quarter. Wells Fargo & Company MN now owns 746,286 shares of the biotechnology company's stock worth $24,851,000 after buying an additional 703,343 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Exelixis by 958.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 2,942 shares of the biotechnology company's stock worth $99,000 after buying an additional 2,664 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Piper Sandler raised their target price on shares of Exelixis from $37.00 to $38.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. HC Wainwright restated a "buy" rating and issued a $40.00 price target on shares of Exelixis in a research note on Thursday, March 27th. UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a report on Thursday, April 17th. Morgan Stanley reiterated an "overweight" rating and set a $47.00 price objective (up previously from $40.00) on shares of Exelixis in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, Exelixis has a consensus rating of "Moderate Buy" and an average price target of $39.35.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.